AUS
NZ
UK
CA
USA
IND
On July 14, 2026, The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) announced it has received its complete production batch of roughly 20,000 units of its flagship BPC-157 transdermal patch. This commercial inventory arrival follows a prior order and represents a significant milestone as the company advances from testing and formulation validation toward commercialization. Each patch delivers 2 mg of BPC-157, with third-party testing verifying 95.5% chromatographic purity and a measured dose of 2.02 mg per patch. With inventory now in hand, the company is set to initiate an initial commercial launch via The Precision Peptide Company website.
Key Points
- The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF), based in Vancouver, British Columbia, is a publicly traded wellness firm specializing in advanced peptide formulations and delivery systems.
- The company has received approximately 20,000 units of its lead product candidate, the BPC-157 transdermal patch, and is preparing to commence sales through its website.
- Each patch contains 2 mg of BPC-157; independent third-party laboratory analysis confirmed 95.5% chromatographic purity, surpassing the widely accepted 5 threshold for high-purity peptides, and a precise dose of 2.02 mg per patch.
- Manufactured in an approved U.S. facility, the company plans North American distribution, initially launching the product on The Precision Peptide Company website.
BPC-157 Transdermal Patch: The Precision Peptide Company's Flagship Product
The Precision Peptide Company positions itself as a publicly traded wellness enterprise developing a next-generation platform for premium peptide formulations. The company merges scientific formulation techniques with innovative delivery technologies, situating its products at the crossroads of biotechnology and scalable consumer wellness.
The BPC-157 transdermal patch is highlighted as the company’s flagship product candidate. The transdermal delivery method is integral to the design, aiming to administer a precise, consistent dose of BPC-157 through the skin. Receiving the 20,000-unit batch marks a pivotal milestone transitioning from testing and formulation validation to active commercialization.
Completion of Approximately 20,000-Unit Production Batch
As detailed in the July 14, 2026 announcement, The Precision Peptide Company has obtained the entire production batch of about 20,000 BPC-157 transdermal patches. This commercial inventory follows a previously disclosed order, indicating the production was commissioned before this update, with receipt of finished goods signifying order fulfillment.
CEO Pratap Sandhu stated, "We ordered 20,000 units and they've now arrived, which moves us into fulfillment as we prepare to begin selling through our website." The company is now positioned to proceed with the initial commercial release of the patch via its website, signaling direct-to-consumer online sales as the primary launch channel.
U.S.-Based Manufacturing and Independent Third-Party Verification
The announcement specifies that the BPC-157 patches are produced in the United States at an approved facility. Additionally, the patches underwent independent testing by a U.S. analytical laboratory, providing third-party confirmation of product composition and quality before commercial release.
CEO Sandhu emphasized the importance of domestic production and testing: "We are proud that our patches are made and tested right here in the U.S. That reflects the standard we've set for ourselves and for our customers." While the specific manufacturing and testing entities remain unnamed, both operate under U.S. standards.
Purity and Dosage Confirmed by Third-Party Testing at 95.5% Chromatographic Purity
A critical technical detail disclosed is the independently verified purity and dosage of BPC-157 per patch. Third-party analysis confirmed 95.5% chromatographic purity, exceeding the 5 threshold widely recognized in the peptide industry as the standard for high-purity products.
Moreover, testing quantified the dose at 2.02 mg per patch, aligning with the company’s target of 2 mg. These findings are consistent with earlier third-party results, validating that the commercial production batch maintains the quality standards established during formulation validation.
Advancing From Validation to Active Commercialization
The company characterizes the receipt of the 20,000-unit batch as a key step in moving from testing and validation to commercialization. Although no exact sales launch date was provided, references to "fulfillment" and preparing "to begin selling through our website" suggest commercial activity is imminent.
This announcement follows a publicly disclosed sequence: formulation and testing, order placement, and now receipt of commercial-grade inventory. This progression aligns with the company’s strategic goal of developing a scalable consumer wellness platform based on peptide science.
North American Distribution and Direct-to-Consumer Sales Strategy
The company’s About section indicates plans for distribution across North America. The initial commercial launch of the BPC-157 patch is slated for The Precision Peptide Company website at www.precisionpeptidecompany.com, implying a direct-to-consumer e-commerce approach.
The announcement does not disclose patch pricing, broader retail or wholesale rollout timelines, or pre-order volumes. However, the broader North American distribution intent suggests the website launch is the first phase of a larger commercial strategy.
CSE Listing and Dual-Market Trading Presence
The Precision Peptide Company trades on the Canadian Securities Exchange under ticker BPC and on the OTCQB in the U.S. under PNGAF, offering access to Canadian and American investors. Headquartered in Vancouver, British Columbia, the company’s dual-market listing supports its North American commercial focus.
The immediate market impact of this announcement was not available at publication time.
Peptide Industry Standards: The 5 Purity Benchmark and BPC-157 Overview
The announcement highlights the 5 chromatographic purity benchmark as a recognized industry standard for high-purity peptides. The company’s independently confirmed 95.5% purity meets and exceeds this criterion, underscoring product quality.
BPC-157 is a peptide commercialized via transdermal delivery. The company’s broader mission involves combining scientific formulation with innovative delivery technologies, with the transdermal patch as the initial commercial product. Regulatory classification, clinical data, or health claims related to BPC-157 were not disclosed.
Forward-Looking Statements and Risk Disclosures
The announcement includes standard Canadian securities forward-looking information disclaimers. Risks cited include regulatory approvals, market acceptance, industry competition, commercialization success, supply chain challenges, and economic conditions.
The company cautions that actual results may differ materially from forward-looking statements and disclaims any obligation to update such information except as required by law. Readers are advised not to place undue reliance on these statements, reflecting typical uncertainties in early-stage product launches.
About The Precision Peptide Company: Business Model and Product Platform
The Precision Peptide Company is a publicly traded wellness firm focused on developing a next-generation platform for premium peptide formulations. It combines scientific formulation expertise with innovative delivery technologies to create products at the intersection of biotechnology and scalable consumer wellness. The BPC-157 transdermal patch is its lead product and first to reach commercial-scale production.
All products are manufactured in an approved U.S. facility, with North American distribution planned. The initial sales channel is the company’s website, www.precisionpeptidecompany.com. Leadership is headed by CEO, Corporate Secretary, and Director Pratap Sandhu.
